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eSpCas9(1.1) (eSpCas9(1.1) HNH ) with Cy3/Cy5 Förster resonance energy transfer (FRET) pairs at positions S355C (within the 'stationary' REC1 domain) and S867C (within the 'mobile' HNH domain) to measure HNH conformational states upon dsDNA binding 12 (Fig. 1c-f and Extended Data Fig. 1c-e ). Whereas SpCas9 HNH stably populated the active state with on-target and mismatched substrates, as observed by steady-state single-molecule FRET (smFRET) ( Fig. 1d ), only ~ 32% of SpCas9-HF1 HNH molecules occupied the HNH active state (E FRET = 0.97) with an on-target substrate, with the remaining ~ 68% trapped in the inactive intermediate state (E FRET = 0.45) ( Fig. 1e ). Of the dynamic molecules (~ 36% of all smFRET traces) observed for SpCas9-HF1 HNH , kinetics analysis further revealed that the HNH transition rate from the inactive state to the active state was approximately eightfold slower than that of WT SpCas9 HNH (~ 3% dynamic molecules 10 ) (Extended Data Fig. 3 ). However, when SpCas9-HF1 HNH was bound to a substrate with a single mismatch at the PAM-distal end (denoted 20-20 bp mm), stable docking of the HNH nuclease was entirely ablated (Fig. 1e ). In addition, eSpCas9(1.1) HNH and other high-fidelity variants 8, 9 reduced the HNH active state in the presence of mismatches ( Fig. 1f and Extended Data Fig. 2c, d) . We therefore propose that high-fidelity variants of Cas9 reduce off-target cleavage by raising the threshold for HNH conformational activation when bound to DNA substrates.
Since the HNH domain does not directly contact nucleic acids at the PAM-distal end 13, [17] [18] [19] , it is likely that a separate domain of Cas9 senses target complementarity to govern HNH domain mobility. Structural studies suggested that a domain within the Cas9 recognition (REC) lobe, called REC3, interacts with the RNA-DNA heteroduplex and undergoes conformational changes upon target binding (Extended Data Fig. 2e , f) 13, 14, [17] [18] [19] . Because the function of this non-catalytic domain was previously unknown, we labelled SpCas9 with Cy3/Cy5 dyes at positions S701C (within the 'mobile' REC3 domain) and S960C (within the 'stationary' RuvC domain) to generate SpCas9 REC3 and observed that the conformational states of REC3 become more heterogeneous as PAM-distal mismatches increase (Extended Data Fig. 4a-c) . To determine whether PAM-distal sensing precedes HNH activation, we deleted REC3 from WT Cas9 (SpCas9∆ REC3) ( Fig. 2a ). Deletion of REC3 decreased the cleavage rate by about 1,000-fold compared with WT Cas9, despite retaining near-WT affinity for the on-target (Extended Data Fig. 4d, e ). Unexpectedly, in vitro complementation of REC3 rescued the on-target cleavage rate by about 100-fold in a concentration-dependent manner ( Fig. 2b and Extended Data Fig. 4d ). Furthermore, the HNH domain in SpCas9∆ REC3 (SpCas9∆ REC3 HNH ) occupied the active state only when REC3 was supplemented in trans (Fig. 2c, d and Extended Data Fig. 4f ). We therefore propose that REC3 acts as an allosteric effector that recognizes the RNA-DNA heteroduplex to allow for HNH nuclease activation.
We next considered allosteric interactions that could couple the discontinuous REC3 and HNH domains. Structural studies suggested that REC2 occludes the HNH domain from the scissile phosphate in the sgRNA-bound state 19 , and undergoes a large outward rotation upon binding to double-stranded DNA (dsDNA) 13, 14 (Fig. 2e ). To test whether the REC2 domain regulates access of HNH to the target strand scissile phosphate, we labelled SpCas9 with Cy3/Cy5 dyes at positions E60C (within the 'stationary' arginine-rich helix) and D273C (within the 'mobile' REC2 domain) to generate SpCas9 REC2 to detect REC2 conformational changes (Extended Data Fig. 1b, c) . We observed reciprocal changes in bulk FRET values ((ratio) A ) 20 between SpCas9 HNH and SpCas9 REC2 across multiple DNA substrates (Extended Data Fig. 4g ), which suggests that the REC2 and HNH domains are tightly coupled to ensure catalytic competence. smFRET experiments further confirmed a large opening of REC2 during the transition from the sgRNA-bound state (E FRET = 0.96) to the target-bound state (E FRET = 0.43) ( Fig. 2e, f) . In contrast to WT SpCas9 REC2 , SpCas9-HF1 REC2 occupies an intermediate state (E FRET = 0.63) when bound to a target with a single PAM-distal mismatch (Fig. 2g ). Together with the observation that the HNH domain of SpCas9-HF1 does not occupy
On-target 20-17 bp mm the active state with PAM-distal mismatches, these experiments suggest that REC2 sterically occludes HNH in the conformational checkpoint when SpCas9 is bound to off-target substrates.
Next, we investigated whether this conformational proofreading mechanism could be rationally exploited to design novel hyper-accurate Cas9 variants. We identified five clusters of residues containing conserved amino acids within 5 Å of the RNA-DNA interface, four of which are located within REC3 and one in the HNH-RuvC Linker 2 (L2) ( Fig. 3a and Extended Data Fig. 5 ). Alone or in combination with Q926A, a substitution within L2 that confers higher specificity 9 , we generated alanine substitutions for each residue within the five different clusters of amino acids (clusters 1-5 ± Q926A) ( Fig. 3a ). We tested whether these cluster mutations affect cleavage accuracy and equilibrium binding in vitro, and found that cluster 1 alone and cluster 2 + Q926A suppressed off-target cleavage while retaining target binding affinities comparable to WT (Extended Data Fig. 6 ). We next screened all cluster variants in human cells using an enhanced GFP (eGFP) disruption assay 5 . On-target activity for cluster 1 was comparable to that of SpCas9-HF1 or eSpCas9(1.1), whereas cluster 2 variants displayed generally lower activity ( Fig. 3b and Extended Data Fig. 7a ). Furthermore, cluster 1 retained high on-target activity (> 70% of WT) at 19 out of 24 endogenous gene sites tested, compared with 18 out of 24 for SpCas9-HF1 and 23 out of 24 for eSpCas9(1.1) ( Fig. 3c and Extended Data Fig. 8a ).
We then focused on the specific contributions of mutations within cluster 1 by restoring each individual mutated residue to its WT identity, along with the Q926A mutation, and tested the resulting variants for on-target editing efficiency in human cells. On-target activity was significantly compromised when N692A/Q695A/Q926A mutations occurred together, but restoring either N692 (cluster 1 N692 + Q926A) or Q695 (cluster 1 Q695 + Q926A) alone led to robust on-target efficiency comparable to cluster 1, signifying differential contributions from these mutations to activity and specificity (Extended Data Figs 7b, c and 8a-c). Using sgRNAs with single mismatches against the endogenous human gene target FANCF site 1, we found that cluster 1 exhibited greater specificity than both SpCas9-HF1 and eSpCas9(1.1) in the middle and PAM-proximal regions of the spacer ( Fig. 3d and Extended Data Fig. 8c ). Additional single mismatch tolerance assays on FANCF sites 4 and 6 further corroborated the superior accuracy of cluster 1 (N692A/M694A/Q695A/H698A, hereafter referred to as HypaCas9) against mismatches at positions 1 through 18; however, single mismatches along FANCF site 2 were still tolerated across all SpCas9 variants tested ( Fig. 3e and Extended Data Fig. 8d, e ).
Next, we performed genome-wide, unbiased identification of double-stranded breaks enabled by sequencing (GUIDE-seq) 6 to compare the genome-wide specificities of WT SpCas9, SpCas9-HF1, eSpCas9(1.1) and HypaCas9 using three sgRNAs previously shown to exhibit substantial off-target effects (FANCF site 2, VEGFA sites 2 and 3) 6,9 , and three previously uncharacterized sgRNAs with a moderate number of in silico predicted off-target sites (FANCF site 6, DNMT1 sites 3 and 4; Extended Data Fig. 9a ). We assessed GUIDEseq tag integration and on-target editing and observed comparable efficiencies among the four nucleases for all six sgRNAs (Extended Data Fig. 9b-d ). Our GUIDE-seq analysis revealed that HypaCas9 exhibits dramatically improved genome-wide specificity compared with WT SpCas9, and showed equivalent or better genome-wide specificity relative to both SpCas9-HF1 and eSpCas9(1.1) for all sgRNAs examined ( Fig. 3f and Extended Data Figs 9e and 10). These results corroborate the enhanced mismatch intolerance of HypaCas9 and demonstrate that its specificity improvements may extend beyond the PAM-proximal and middle regions of the spacer sequence.
To biochemically validate cleavage specificity in the middle region of the spacer with HypaCas9, we measured cleavage rates against the FANCF site 1 sequence with or without internal mismatches. Although HypaCas9 retained on-target activity comparable to WT and SpCas9-HF1 in human cells, its in vitro cleavage rate was slightly reduced for the one target site examined (Fig. 4a ). However, the GUIDE-seq detected off-target sites 
WT SpCas9
SpCas9-HF1 cleavage rate with internally mismatched substrates was considerably slower compared with WT and SpCas9-HF1, which may be explained by the altered threshold of HNH activation (Fig. 4a, b ).
Our findings provide direct evidence to support previous speculation that Cas9 relies on protospacer sensing to enable accurate targeting 21, 22 . In particular, we propose that REC3 binding to the RNA-DNA duplex is necessary for re-orienting REC2, which enables HNH docking at the active site (Extended Data Fig. 4h, i) . Mutation of residues within REC3 that are involved in RNA-DNA heteroduplex recognition, such as those mutated in HypaCas9 or SpCas9-HF1, prevents transitions by the REC2 domain, which more stringently traps the HNH domain in the conformational checkpoint in the presence of mismatches ( Fig. 4c and Extended Data Fig. 10 ). Curiously, nearly all of the amino acids within the cluster variants were strongly conserved (Extended Data Fig. 5 ), suggesting that these residues may also be involved in protospacer sensing and HNH nuclease activation across Cas9 orthologues. Furthermore, this observation may address how nature apparently has not selected for a highly precise Cas9 protein, whose native balance between mismatch tolerance and specificity may be optimized for host immunity. Our study delineates a general strategy for improving Cas9 specificity by tuning the natural conformational threshold, and offers opportunities for rational design of hyper-accurate Cas9 variants that do not compromise efficiency.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Protein purification and dye labelling. S. pyogenes Cas9 and truncation derivatives were cloned into a custom pET-based expression vector containing an N-terminal His 6 -tag, maltose-binding protein (MBP) and TEV protease cleavage site. Point mutations were introduced by Gibson assembly or around-the-horn PCR and verified by DNA sequencing. Proteins were purified as described 23 , with the following modifications: after Ni-NTA affinity purification and overnight TEV cleavage at 4 °C, proteins were purified over an MBPTrap HP column connected to a HiTrap Heparin HP column for cation exchange chromatography. The final gel filtration step (Superdex 200) was carried out in elution buffer containing 20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 5% (v/v) glycerol and 1 mM TCEP. For FRET experiments, Cy3/Cy5-dye positions were selected within a cysteine-free Cas9 protein on the basis of a structural alignment of the sgRNA-bound (4ZT0) to dsDNA-bound (5F9R) structures. Each FRET pair consisted of one cysteine substitution within the 'mobile' domain (HNH, REC2 or REC3) and another within the relatively 'stationary' domain (REC1, arginine-rich helix or RuvC), such that the inter-residue distance change from the sgRNA-bound to dsDNA-bound states was between 10 and 90 Å (Extended Data Fig. 10 ). Dye-labelled Cas9 samples were subsequently prepared as described 12 . A list of all protein variants and truncations is in Supplementary Table 2 . Nucleic acid preparation. sgRNA templates were PCR amplified from a pUC19 vector containing a T7 promoter, 20 nucleotide target sequence and optimized sgRNA scaffold. The amplified PCR product was extracted with phenol:chloroform:isoamyl alcohol and served as the DNA template for sgRNA transcription reactions, which were performed as described 24 . DNA oligonucleotides and 5′ end biotinylated DNAs ( Supplementary Table 3 ) were synthesized commercially (Integrated DNA Technologies), and DNA duplexes were prepared and purified by native PAGE as described 23 . DNA cleavage and binding assays. DNA duplex substrates were 5′ -32 Pradiolabelled on both strands. For cleavage experiments, Cas9 and sgRNA were pre-incubated at room temperature for at least 10 min in 1× binding buffer (20 mM Tris-HCl, pH 7.5, 100 mM KCl, 5 mM MgCl 2 , 1 mM DTT, 5% glycerol, 50 μ g ml −1 heparin) before initiating the cleavage reaction by addition of DNA duplexes. For REC3 in vitro complementation experiments, 100 nM SpCas9∆ REC3-sgRNA complexes were pre-incubated with tenfold molar excess of REC3 for at least 10 min at room temperature before addition of 1 nM radiolabelled substrate. For REC3 titration experiments, 100 nM SpCas9∆ REC3-sgRNA complexes were separately pre-incubated with 0, 10, 20, 50, 100, 200, 500, and 1,000 nM REC3 for at least 10 min at room temperature before addition of 1 nM radiolabelled substrate; reactions were quenched after 10 min with an equal volume of buffer containing 50 mM EDTA, 0.02% bromophenol blue, and 90% (vol/vol) formamide. DNA cleavage experiments were performed and analysed as previously described 12 .
DNA binding assays were conducted using increasing concentrations of SpCas9 variant-sgRNA complexes (0.1, 1, 3, 10, 30, 100, 300, and 1,000 nM) in 1× binding buffer without MgCl 2 + 1 mM EDTA, and reactions were incubated with < 0.1 nM radiolabelled duplex substrate at room temperature for 2 h. DNA-bound complexes were resolved on 8% native PAGE (0.5× TBE + 1 mM EDTA, without MgCl 2 ) at 4 °C, as previously described 10 . Experiments were replicated at least three times, and presented gels are representative results. Bulk FRET experiments. All bulk FRET assays were performed at room temperature in 1× binding buffer, containing 50 nM SpCas9 HNH (C80S/S355C/ C574S/S867C labelled with Cy3/Cy5), SpCas9∆ REC3 HNH (M1-N497,GGS,V713-D1368 + C80S/S355C/C574S/S867C) or SpCas9 REC2 (E60C/C80S/D273C/C574S labelled with Cy3/Cy5) with 200 nM sgRNA and DNA substrate where indicated. Fluorescence measurements were collected and analysed as described 12 . For REC3 in vitro complementation FRET experiments, SpCas9∆ REC3 HNH and sgRNA were pre-incubated with tenfold molar excess of REC3 for at least 10 min at room temperature before measuring bulk fluorescence. Sample preparation for smFRET assay. MicroSurfaces supplied 99% PEG and 1% biotinylated-PEG coated quartz slides. Sample preparation was performed as previously described 10 . Briefly, the glass surface was pre-blocked with casein (10 mg ml −1 ) for 10 min. The sample chamber was washed with 1× binding buffer, then incubated with 20 μ l streptavidin (1 mg ml −1 ) for 10 min. Unbound streptavidin was washed away with 40 μ l of 1× binding buffer.
To immobilize SpCas9 on its DNA substrate, 2.5 nM biotinylated DNA substrate was introduced and incubated in the sample chamber for 5 min. Excess DNA was washed with 1× binding buffer. SpCas9-sgRNA complexes were prepared by mixing 50 nM Cas9 and 50 nM sgRNA in 1× binding buffer and incubated for 10 min at room temperature. SpCas9-sgRNA was diluted to 100 pM, introduced to sample chamber and incubated for 10 min. Before data acquisition, 20 μ l imaging buffer (1 mg ml −1 glucose oxidase, 0.04 mg ml −1 catalase, 0.8% dextrose (w/v) and 2 mM Trolox in 1× binding buffer) was flown into chamber. The REC3 in vitro complementation assay was performed similarly to steadystate FRET experiments: 2.5 nM biotinylated DNA substrate (on-target) was immobilized on the surface, and excess DNA was washed with 1× binding buffer. SpCas9-sgRNA complexes were prepared by mixing 50 nM SpCas9∆ REC3 and 50 nM sgRNA in 1× binding buffer and incubated for 10 min at room temperature. SpCas9-sgRNA was diluted to 100 pM, introduced to the sample chamber and incubated for 10 min. Before data acquisition, 20 μ l imaging buffer was flowed into the chamber. After data acquisition, the sample chamber was washed with 1× binding buffer. Imaging buffer (20 μ l) supplemented with 1 μ M REC3 was flowed into the sample chamber and incubated for 10 min. After incubation, data for REC3 complementation were collected. Microscopy and data analysis. A prism-type TIRF microscope was set up using a Nikon Ti-E Eclipse inverted fluorescent microscope equipped with a 60× , 1.20 numerical aperture Plan Apo water objective and the Perfect Focus System (Nikon). A 532-nm solid state laser (Coherent Compass) and a 633-nm HeNe laser (JDSU) were used for Cy3 and Cy5 excitation, respectively. Cy3 and Cy5 fluorescence was split into two channels using an Optosplit II image splitter (Cairn Instruments) and imaged separately on the same electron-multiplied charged-coupled device camera (512 pixels × 512 pixels, Andor Ixon EM + ). Effective pixel size of the camera was set to 267 nm after magnification. Movies for steady-state FRET measurements were acquired at 10 Hz under 0.3 kW cm −2 532-nm excitation. Steady-state and dynamic FRET data analysis was performed as described previously 10 . Briefly, for steady-state FRET analysis, two fluorescent channels were registered with each other using fiducial markers (20 nm diameter Nile Red Beads, Life Technologies) to determine the Cy3/Cy5 FRET pairs. Cy3/Cy5 pairs that photobleached in one step and showed anti-correlated signal changes were used to build histograms. FRET values were corrected for donor leakage and the histograms were normalized to determine the percentage of distinct FRET populations. Only samples showing greater than 3% of molecules with active transitions were subjected to dynamic FRET analysis. Human cell culture and transfection. Descriptions of nuclease and guide RNA plasmids used for human cell culture are available in Supplementary Tables 2 and 3 . Nuclease variants were generated by isothermal assembly into JDS246 (Addgene 43861) 5 , and guide RNAs were cloned into BsmBI-digested BPK1520 (Addgene 65777) 25 . Both U2OS cells (a gift from T. Cathomen, Freiburg) and U2OS-eGFP cells (encoding a single integrated copy of a pCMV-eGFP-PEST cassette) 26 were cultured at 37 °C with 5% CO 2 in advanced DMEM containing 10% heat-inactivated fetal bovine serum, 2 mM GlutaMax, penicillin-streptomycin, and 400 μ g ml −1 Geneticin (for U2OS-eGFP cells only). Cell culture reagents were purchased from Thermo Fisher Scientific, cell line identities were validated by STR profiling (American Type Culture Collection, ATCC) and deep-sequencing, and cell culture supernatant was tested twice a month for mycoplasma. Transfections were performed using a Lonza 4-D Nucleofector with the SE Kit and the DN-100 program on ~ 200,000 cells with 750 ng of nuclease and 250 ng of guide RNA plasmids. Human cell eGFP disruption assay. eGFP disruption experiments were performed as previously described 5, 26 . Briefly, transfected cells were analysed ~ 52 h after transfection for loss of eGFP fluorescence using a Fortessa flow cytometer (BD Biosciences). Background loss was determined by gating a negative control transfection (containing nuclease and empty guide RNA plasmid) at ~ 2.5% for all experiments. T7 endonuclease I assay. Roughly 72 h after transfection, genomic DNA was extracted from U2OS cells using an Agencourt DNAdvance Genomic DNA Isolation Kit (Beckman Coulter Genomics), and T7 endonuclease I (T7E1) assays were performed as previously described 26 . Briefly, 600-to 800-nucleotide amplicons surrounding on-target sites were amplified from ~ 100 ng of genomic DNA using Phusion Hot-Start Flex DNA Polymerase (New England Biolabs, NEB) using the primers listed in Supplementary Table 3 . PCR products were visualized (using a QIAxcel capillary electrophoresis instrument, Qiagen) and purified (Agencourt Ampure XP cleanup, Beckman Coulter Genomics). Denaturation and annealing of ~ 200 ng of the PCR product was followed by digestion with T7EI (NEB). Digestion products were purified (Ampure) and quantified (QIAxcel) to approximate the mutagenesis frequencies induced by Cas9-sgRNA complexes. GUIDE-seq. GUIDE-seq experiments were performed with WT SpCas9, SpCas9-HF1, eSpCas9(1.1) and HypaCas9 for six different sgRNAs, essentially as previously described 6 . Briefly, U2OS cells were transfected as described above with the addition of 100 pmol of an end-protected double-stranded oligonucleotide (dsODN) GUIDE-seq tag. Approximately 72 h after nucleofection, genomic DNA was extracted and gene disruption was quantified by T7E1 assay (as described above). GUIDE-seq tag-integration efficiencies were assessed using restriction fragment length polymorphism (RFLP) assays as previously described 9 . Briefly, PCR reactions amplified from ~ 100 ng of genomic DNA from GUIDE-seq treated samples, using Phusion Hot-Start Flex DNA Polymerase (NEB), were treated Letter reSeArCH with 20 U NdeI (NEB) for 3 h. Digested products were purified (Ampure) and quantified (QIAxcel) to approximate GUIDE-seq tag-integration efficiencies. To perform GUIDE-seq, sample libraries were assembled as previously described 6 and sequenced on an Illumina MiSeq machine. Data were analysed using open-source guideseq software (version 1.1) 27 . GUIDE-seq data can be found in Supplementary  Table 1 , and are deposited with the NCBI Sequence Read Archive. Potential alternative alignments shown in Supplementary Table 1 , resulting from RNA or DNA bulges 28 , depict one of many possible alternative alignments. Data availability. Plasmids encoding the high-fidelity SpCas9 variants described in this manuscript have been deposited with the non-profit plasmid distribution service Addgene (http://www.addgene.org/). All sequencing data from this study are available through the NCBI Sequence Read Archive under accession number SRP116962. The authors declare that all other data supporting the findings of this study are available within the paper and its Supplementary Information files. 
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